Profound Medical (TSE:PRN) has released an update.
Profound Medical Corp., known for its innovative, incision-free medical therapies, is set to present its business updates at the Stifel 2024 Healthcare Conference. The company’s TULSA-PRO and Sonalleve technologies offer promising solutions for prostate disease and uterine fibroids, respectively, with significant regulatory approvals across major markets.
For further insights into TSE:PRN stock, check out TipRanks’ Stock Analysis page.
